Cellebrite DI (CLBT) Expected to Announce Earnings on Thursday

Cellebrite DI (NASDAQ:CLBT) is expected to be posting its Q2 2025 quarterly earnings results before the market opens on Thursday, August 14th. Analysts expect Cellebrite DI to post earnings of $0.11 per share and revenue of $112.33 million for the quarter.

Cellebrite DI (NASDAQ:CLBT) last issued its quarterly earnings results on Wednesday, May 14th. The company reported $0.10 EPS for the quarter, topping the consensus estimate of $0.09 by $0.01. Cellebrite DI had a negative net margin of 46.34% and a positive return on equity of 35.36%. The business had revenue of $107.55 million for the quarter, compared to analysts’ expectations of $109.36 million. During the same quarter last year, the company posted $0.08 earnings per share. The company’s quarterly revenue was up 20.0% compared to the same quarter last year. On average, analysts expect Cellebrite DI to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Cellebrite DI Stock Performance

Shares of CLBT stock opened at $13.91 on Wednesday. Cellebrite DI has a one year low of $13.10 and a one year high of $26.30. The company’s 50-day simple moving average is $15.08 and its 200-day simple moving average is $17.96. The stock has a market capitalization of $3.33 billion, a price-to-earnings ratio of -14.49, a PEG ratio of 2.73 and a beta of 1.27.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the stock. Wall Street Zen cut shares of Cellebrite DI from a “buy” rating to a “hold” rating in a research report on Saturday, August 2nd. JPMorgan Chase & Co. reduced their price target on shares of Cellebrite DI from $29.00 to $25.00 and set an “overweight” rating on the stock in a research report on Monday, May 12th. Finally, Needham & Company LLC restated a “buy” rating and issued a $24.00 price target on shares of Cellebrite DI in a research report on Friday, June 6th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Cellebrite DI has an average rating of “Moderate Buy” and a consensus target price of $22.43.

Institutional Trading of Cellebrite DI

A hedge fund recently raised its stake in Cellebrite DI stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) by 16.8% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 173,013 shares of the company’s stock after buying an additional 24,881 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC owned approximately 0.07% of Cellebrite DI worth $3,362,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 45.88% of the company’s stock.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.